The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: A randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial 

Published in 2023 this randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial assessed for safety and tolerability of NMN on metabolic parameters that relate to aging. The results confirmed that orally administered NMN is absorbed  and quickly converted into NAD in human blood. 

NAD blood levels were increased in a dose dependent manner.  

References:

Yi L, et al. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. Geroscience. 2023 Feb;45(1):29-43. doi: 10.1007/s11357-022-00705-1. Epub 2022 Dec 8. PMID: 36482258; PMCID: PMC9735188.